[8] The process begins when insulin binds to its receptor (IR) located on neuronal and glial cell membranes
Regulatory approval for use with MiniMed 780G: On May 2, 2023, Medtronic Canada announced it received a Health Canada licence for the Guardian 4 sensor to be used in conjunction with the MiniMed 780G system for management of type 1 diabetes
This third component is what distinguishes retatrutide from currently approved agents
Typically, candidates should have a body mass index (BMI) of 30 or higher, categorically defining obesity
GLP-1 (glucagon-like peptide-1) agonists are injectables that mimic the hormone glucagon, which the body produces to control blood glucose levels
Cardiovascular outcomes trials such as LEADER (liraglutide), SUSTAIN-6 (semaglutide), and REWIND (dulaglutide) have shown that certain GLP-1 receptor agonists significantly reduce major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in patients with type 2 diabetes and established cardiovascular disease or multiple risk factors
